Form 4: Candel Therapeutics Director Gary Nabel Granted Stock Options

Candel Therapeutics, Inc. Director Gary J. Nabel was granted 14,240 stock options with an exercise price of $4.94, vesting over time.

Summary

• Gary J. Nabel, a Director of Candel Therapeutics, Inc. (CADL), was granted 14,240 stock options.
• The options have an exercise price of $4.94 per share.
• The grant date for these options was June 17, 2025.
• The options are subject to time-based vesting, becoming exercisable upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders.
• Vesting will cease if Mr. Nabel resigns or ceases to serve as a director, unless the Board determines otherwise.
• The options have an expiration date of June 17, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive signal of continued alignment and incentive, though it's a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of stock options to Director Gary J. Nabel indicates continued alignment of his interests with those of shareholders, as the options' value is tied to the company's stock performance.
• The options serve as an incentive for Mr. Nabel to remain engaged with the company's strategic direction and performance.

Risks

• The value of the stock options is dependent on the future market price of Candel Therapeutics, Inc. common stock exceeding the exercise price of $4.94.
• Vesting of the options is contingent upon Mr. Nabel's continued service as a director, with vesting ceasing upon resignation unless otherwise determined by the Board.

Future Outlook

This Form 4 filing pertains to an individual's equity compensation and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine disclosure of an insider transaction (stock option grant) and does not provide broader industry context or trends. It reflects standard equity compensation practices for directors in the biotechnology or pharmaceutical sector.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders by tying compensation to stock performance. Dilution from future exercise is minimal for this number of shares.

Next Steps

• The stock options will vest upon the earlier of June 17, 2026, or the date of the next Annual Meeting of Stockholders.
• The Reporting Person will continue to serve as a Director of Candel Therapeutics, Inc. for the options to vest.

Key Dates

Keywords

Candel Therapeutics, CADL, SEC Form 4, Stock Option Grant, Director Compensation, Equity Compensation, Insider Transaction, Gary J. Nabel